Drug Type ASO |
Synonyms Antisense Oligonucleotide (ASO) Programs, Antisense Oligonucleotide Programs (ACADIA), MECP2 ASO (ACADIA/Stoke Therapeutics) |
Target |
Action modulators |
Mechanism MECP2 modulators(Methyl-CpG-binding protein 2 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rett Syndrome | Preclinical | United States | 30 Oct 2023 | |
Rett Syndrome | Preclinical | United States | 30 Oct 2023 |